Table 3.
Risk factors for bacterial infections in COVID-19 hospitalized patients
| Univariate analysis* | Multivariate analysis** | |||
|---|---|---|---|---|
| OR (95% CI) | p value | OR (95% CI) | p value | |
| Baseline conditions | ||||
| Age | 1.02 (1.01–1.03) | 0.007 | 1.02 (1.01–1.04) | 0.009 |
| DM | 1.88 (1.26–2.81) | 0.002 | 1.60 (0.99–2.49) | 0.059 |
| Neurological disease | 1.68 (1.08–2.60) | 0.022 | 1.69 (1.01–2.82) | 0.046 |
| Kidney disease | 2.23 (1.30–3.82) | 0.003 | 1.221 (0.64–2.29) | 0.555 |
| Active neoplasm | 2.66 (1.52–4.65) | 0.001 | 1.047 (0.50–2.20) | 0.903 |
| Immunosuppression | 4.26 (2.82–6.45) | < 0.001 | 4.41 (2.76–7.06) | < 0.001 |
| Outcome | ||||
| ARDS | 3.17 (1.77–5.68) | < 0.001 | 1.34 (0.70–2.55) | 0.375 |
| ICU admission | 16.69 (10.80–25.81) | < 0.001 | 21.36 (13.21–34.55) | < 0.001 |
| Treatment | ||||
| Steroids | 2.46 (1.63–3.70) | < 0.001 | 0.94 (0.55–1.61) | 0.828 |
| Tocilizumab | 3.29 (2.27–4.76) | < 0.001 | 0.66 (0.12–3.75) | 0.636 |
| Steroids* + TocilizumabT | 2.43 (1.66–3.58) | < 0.001 | 1.31 (0.80–2.16) | 0.282 |
Ods ratio, confidence intervals and p-values marked with bold indicate statistically significance
OR Odds ratio, CI Confidence interval, DM Diabetes mellitus, ARDS Acute respiratory distress syndrome, ICU Intensive care Unit
T: Product term between steroids and tocilizumab treatment